Caplin Point Laboratories’ wholly owned subsidiary -- Caplin One Labs has completed its state-of-the-art Oncology facility at Kakkalur, near Chennai, and immediate commencement of operations. The total investment commitment for this facility is Rs 150 crore, funded entirely from internal accruals. To start with, the unit will focus on manufacturing a range of Oral Solid Dosage Oncology products, with the Injectable division to commence operations in the next few months. The company plans to expand the portfolio to over 50 oncology products progressively.
The facility will manufacture tablets (both coated & uncoated), capsules, and injections, catering to the growing demand for high-quality pharmaceuticals in the oncology segment. Initially, these oncology products will be targeted at Latin American countries, leveraging Caplin Group's established presence in these markets.
In the medium term, Caplin One Labs aims to launch these oncology products in regulated markets such as the US, EU, Mexico, and others. The facility's compliance with USFDA standards from the outset is expected to streamline the approval process, ensuring swift market entry and availability of these critical treatments to patients worldwide. Caplin Group remains dedicated to advancing healthcare solutions, improving patient outcomes, and making a positive impact on communities globally.
Caplin Point Laboratories is engaged mainly in manufacturing a wide range of Ointments, Creams and other External application preparations in addition to the regular segments of pharmaceutical formulations.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1854.15 |
| Dr. Reddys Lab | 1350.75 |
| Cipla | 1497.80 |
| Lupin | 2357.65 |
| Zydus Lifesciences | 1001.20 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Limited to the first 10 users today!
Practical Stock Investing Hand Book
By - Raymond Moses
Founder of MoneyWorks4Me | Consultant | Trainer | Author | TEDx Speaker
Register & Get Instant Access!Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
